Healthcare company Fresenius Kabi has introduced a new single-needle venous access option for the Amicusextracorporeal photopheresis (ECP) system.
In 2019, the Amicus Blue System featuring online ECP was introduced in Europe, enabling venous access exclusively through double-needle.
Fresenius Kabi MedTech president Christian Hauer said: “We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access.
“This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs.”
The company has launched the latest software versions: v6.1 for the Amicus Separator and v2.1 for the Phelix Photoactivation Device.
It also introduced a new single-use disposable kit that can be customised to provide venous access through single or double-needle.
The system allows clinicians to seamlessly switch between single and double-needle access during the procedure.
The CE mark for the Amicus ECP system was granted for the approved indication of palliative treatment of the skin manifestations of cutaneous T cell lymphoma that is unresponsive to other treatments.
The ECP system consists of the Amicus Separator, the Phelix Photoactivation Device and Amicus ECP Apheresis Kits.
Furthermore, the separator system is approved in Europe and the US for therapeutic plasma exchange, mononuclear cell collection, red blood cell exchange and platelet collection.
Meanwhile, the Amicus ECP System is not yet approved for use in the US.